Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
SAN DIEGO, May 07, 2018 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 10, 2018 at 5:30 PM Eastern Time.
The dial-in information is as follows:
Dial-In Number: +1.877.402.3914
Conference ID: 7194327
Prior to the webcast at approximately 4:30 PM Eastern Time on May 10, Cytori will issue its first quarter earnings release which will review Cytori’s first quarter performance. The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.
About Cytori Therapeutics, Inc.
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information, visit www.cytori.com.
Cytori Therapeutics, Inc.
Tiago Girao, 1.858.458.0900
[email protected]
